A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Protara Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 151,618 shares of TARA stock, worth $347,205. This represents 0.0% of its overall portfolio holdings.

Number of Shares
151,618
Previous 80,518 88.3%
Holding current value
$347,205
Previous $167,000 65.87%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.7 - $2.4 $120,870 - $170,640
71,100 Added 88.3%
151,618 $277,000
Q2 2024

Aug 14, 2024

BUY
$1.96 - $4.14 $104,860 - $221,489
53,500 Added 198.02%
80,518 $167,000
Q4 2023

Feb 14, 2024

SELL
$1.12 - $1.93 $896 - $1,544
-800 Reduced 2.88%
27,018 $50,000
Q3 2023

Nov 14, 2023

SELL
$1.64 - $2.93 $5,740 - $10,255
-3,500 Reduced 11.18%
27,818 $46,000
Q2 2023

Aug 14, 2023

SELL
$2.27 - $3.59 $681 - $1,077
-300 Reduced 0.95%
31,318 $74,000
Q1 2023

May 15, 2023

SELL
$2.76 - $3.91 $43,056 - $60,996
-15,600 Reduced 33.04%
31,618 $98,000
Q4 2022

Feb 14, 2023

SELL
$2.43 - $3.7 $12,636 - $19,240
-5,200 Reduced 9.92%
47,218 $126,000
Q3 2022

Nov 14, 2022

SELL
$2.96 - $4.27 $2,072 - $2,988
-700 Reduced 1.32%
52,418 $155,000
Q2 2022

Aug 15, 2022

SELL
$2.8 - $5.33 $35,840 - $68,224
-12,800 Reduced 19.42%
53,118 $156,000
Q1 2022

May 16, 2022

SELL
$4.19 - $6.9 $439,950 - $724,500
-105,000 Reduced 61.43%
65,918 $337,000
Q4 2021

Feb 14, 2022

BUY
$6.15 - $7.76 $12,915 - $16,296
2,100 Added 1.24%
170,918 $1.15 Million
Q3 2021

Nov 15, 2021

BUY
$6.38 - $9.3 $704,990 - $1.03 Million
110,500 Added 189.48%
168,818 $1.17 Million
Q2 2021

Aug 16, 2021

BUY
$8.68 - $16.99 $401,016 - $784,937
46,200 Added 381.25%
58,318 $568,000
Q1 2021

May 17, 2021

SELL
$13.75 - $23.86 $101,750 - $176,564
-7,400 Reduced 37.91%
12,118 $191,000
Q4 2020

Feb 16, 2021

BUY
$16.97 - $25.34 $331,220 - $494,586
19,518 New
19,518 $473,000

Others Institutions Holding TARA

About Protara Therapeutics, Inc.


  • Ticker TARA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 11,267,400
  • Market Cap $25.8M
  • Description
  • Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chlorid...
More about TARA
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.